The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET

Alzheimer's and Dementia

Volumn 11, Issue 1, 2015, Pages 1-15.e4

  Klunk, William E ^a,b   Koeppe, Robert A ^c   Price, Julie C ^b   Benzinger, Tammie L ^a,d   Devous, Michael D ^e   Jagust, William J ^f   Johnson, Keith A ^a   Mathis, Chester A ^b   Minhas, Davneet ^b   Pontecorvo, Michael J ^g   Rowe, Christopher C ^h   Skovronsky, Daniel M ^g   Mintun, Mark A ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g AVID RADIOPHARMACEUTICALS   (United States)

^h AUSTIN HEALTH   (Australia)

Author keywords

Amyloid imaging; Centiloid scale; Pittsburgh compound B; Positron emission tomography; Standardize

Indexed keywords

CARBON 11; FLUORINE 18; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID; ANILINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CEREBELLAR PEDUNCLE; CLINICAL DEMENTIA RATING; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; EFFECT SIZE; HUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEST RETEST RELIABILITY; WHITE MATTER; AGED; BRAIN; CALIBRATION; COMPUTER ASSISTED DIAGNOSIS; METABOLISM; MIDDLE AGED; SCINTISCANNING; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; CALIBRATION; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84922779468     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.07.003     Document Type: Article

References (38)

1. Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement 2011;7:171-4.
2. Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011;7:474-4854.
3. Boccardi M, Bocchetta M, Ganzola R, Robitaille N, Redolfi A, Duchesne S, et al. Operationalizing protocol differences for EADCADNI manual hippocampal segmentation. Alzheimers Dement 2013; http://dx.doi.org/10.1016/j.jalz.2013.03.001 (in press).
4. Frisoni GB, Bocchetta M, Chetelat G, Rabinovici GD, De Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81:487-500.
5. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement 2012;8:65-73.
6. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013;9:137-40.
7. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52.
8. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2:975-84.
9. Oh H, Madison C, Haight TJ, Markley C, Jagust WJ. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol Aging 2012;33:2746-55.
10. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
11. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-31.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
13. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairmentamong the elderly. Arch Neurol 2008;65:1509-17.
14. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25.
15. Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205-12.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
17. Schwertman NC, De Silva R. Identifying outliers with sequential fences. Computational Statistics & Data Analysis 2007;51:3800-10.
18. Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 2013;71:207-15.
19. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolismmay modulate the cognitive effects of Ab in mild cognitive impairment: an example of brain reserve. J Neurosci 2009;29:14770-8.
20. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47.
21. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999;7:254-66.
22. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95-113.
23. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-51.
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
25. Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci 2001;356:1293-322.
26. Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36:1629-38.
27. Yaqub M, Tolboom N, Boellaard R, Van Berckel BN, Van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage 2008;42:76-86.
28. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457-68.
29. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79:1094-108.
30. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013;54:1420-7.
31. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
32. Yamane T, Ikari Y, Nishio T, Ishii K, Kato T, Ito K, et al. Visual-statistical interpretation of 18F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol 2014;35:244-9.
33. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-9.
34. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-84.
35. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009;66:1537-44.
36. Cohen AD, Bi W, Weissfeld LA, Aizenstein HA, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 2012;71:207-15.
37. Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012;59:1152-60.
38. Klunk W, Cohen A, Bi W, Weissfeld L, Aizenstein H, McDade E, et al. Why we need two cutoffs for amyloid imaging: early versus Alzheimer'slike amyloid-positivity. Alzheimers Dement 2012;8:P453-4.